Standard
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. / Torp-Pedersen, Christian; Raev, Dimitar H; Dickinson, Garth; Butterfield, Noam N; Mangal, Brian; Beatch, Gregory N.
In:
Circulation. Arrhythmia and Electrophysiology, Vol. 4, No. 5, 2011, p. 637-43.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Torp-Pedersen, C, Raev, DH, Dickinson, G, Butterfield, NN, Mangal, B & Beatch, GN 2011, '
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion',
Circulation. Arrhythmia and Electrophysiology, vol. 4, no. 5, pp. 637-43.
https://doi.org/10.1161/CIRCEP.111.962340
APA
Torp-Pedersen, C., Raev, D. H., Dickinson, G., Butterfield, N. N., Mangal, B., & Beatch, G. N. (2011).
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Circulation. Arrhythmia and Electrophysiology,
4(5), 637-43.
https://doi.org/10.1161/CIRCEP.111.962340
Vancouver
Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Circulation. Arrhythmia and Electrophysiology. 2011;4(5):637-43.
https://doi.org/10.1161/CIRCEP.111.962340
Author
Torp-Pedersen, Christian ; Raev, Dimitar H ; Dickinson, Garth ; Butterfield, Noam N ; Mangal, Brian ; Beatch, Gregory N. / A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. In: Circulation. Arrhythmia and Electrophysiology. 2011 ; Vol. 4, No. 5. pp. 637-43.
Bibtex
@article{4f3e94acac2e4569ab4e69f15de9ae8d,
title = "A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion",
abstract = "Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.",
author = "Christian Torp-Pedersen and Raev, {Dimitar H} and Garth Dickinson and Butterfield, {Noam N} and Brian Mangal and Beatch, {Gregory N}",
year = "2011",
doi = "http://dx.doi.org/10.1161/CIRCEP.111.962340",
language = "English",
volume = "4",
pages = "637--43",
journal = "Circulation: Arrhythmia and Electrophysiology",
issn = "1941-3149",
publisher = "Lippincott Williams & Wilkins",
number = "5",
}
RIS
TY - JOUR
T1 - A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion
AU - Torp-Pedersen, Christian
AU - Raev, Dimitar H
AU - Dickinson, Garth
AU - Butterfield, Noam N
AU - Mangal, Brian
AU - Beatch, Gregory N
PY - 2011
Y1 - 2011
N2 - Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.
AB - Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.
U2 - http://dx.doi.org/10.1161/CIRCEP.111.962340
DO - http://dx.doi.org/10.1161/CIRCEP.111.962340
M3 - Journal article
VL - 4
SP - 637
EP - 643
JO - Circulation: Arrhythmia and Electrophysiology
JF - Circulation: Arrhythmia and Electrophysiology
SN - 1941-3149
IS - 5
ER -
